Premium
α v β 3 –Targeted nanotherapy suppresses inflammatory arthritis in mice
Author(s) -
Zhou Hui-fang,
Chan Happy W.,
Wickline Samuel A.,
Lanza Gregory M.,
Pham Christine T. N.
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.09-129874
Subject(s) - medicine , arthritis , fumagillin , angiogenesis , inflammatory arthritis , inflammation , alpha (finance) , ankle , rheumatoid arthritis , pharmacology , immunology , surgery , construct validity , patient satisfaction
The purpose of this study was to assess whether an alternative treatment approach that targets angiogenesis, delivered through ligand‐targeted nanotherapy, would ameliorate inflammatory arthritis. Arthritis was induced using the K/BxN mouse model of inflammatory arthritis. After arthritis was clearly established, mice received three consecutive daily doses of α v β 3– targeted fumagillin nanoparticles. Control groups received no treatment or α v β 3– targeted nanoparticles without drugs. Disease score and paw thickness were measured daily. Mice that received α v β 3– targeted fumagillin nanoparticles showed a significantly lower disease activity score (mean score of 1.4±0.4; P <0.001) and change in ankle thickness (mean increase of 0.17±0.05 mm; P <0.001) 7 d after arthritis induction, whereas the group that received α v β 3– targeted nanoparticles without drugs exhibited a mean arthritic score of 9.0 ± 0.3 and mean change in ankle thickness of 1.01 ± 0.09 mm. Meanwhile, the group that received no treatment showed a mean arthritic score of 9.8 ± 0.5 and mean change in ankle thickness of 1.05 ± 0.10 mm. Synovial tissues from animals treated with targeted fumagillin nanoparticles also showed significant decrease in inflammation and angiogenesis and preserved proteoglycan integrity. Ligand‐targeted nanotherapy to deliver antiangiogenic agents may represent an effective way to treat inflammatory arthritis.—Zhou, H.‐F., Chan, H. W., Wickline, S. A., Lanza, G. M., Pham, C. T. N. α v β 3– Targeted nanotherapy suppresses inflammatory arthritis in mice. FASEB J. 23, 2978–2985 (2009). www.fasebj.org